Merck News (NYSE:MRK)

DateTimeSource
Headline
08/23/20163:03AMDJNDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
By Jonathan D. Rockoff Pfizer's $14 billion deal to buy Medivation and its prostate-cancer drug Xtandi is the latest in a long line of big pharmaceutical company acquisitions of smaller companies with prized assets. Sometimes, the big pharmaceutical companies do the deals to plug in the sales of already approved and... More...>>
08/22/201612:52PMDJNPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
By Jonathan D. Rockoff Pfizer's $14 billion deal to buy Medivation and its prostate-cancer drug Xtandi is the latest in a long line of big pharmaceutical company acquisitions of smaller companies with prized assets. Sometimes, the big pharmaceutical companies do the deals to plug in the sales of already approved and... More...>>
08/09/20163:03AMDJNBotox Maker Allergan's Revenue Climbs, but Loss More Than Doubles -- WSJ
By Jonathan D. Rockoff and Austen Hufford Allergan PLC's chief executive said the company "doesn't need" to make a big acquisition, as the drugmaker reported strong sales of many products but a doubling of its quarterly loss, due to the impact of discontinued operations. The Wall Street Journal reported... More...>>
08/08/20165:05PMBWResults from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir & grazoprevir) in Patients with Chronic Hepatitis C Rec...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR. C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6... More...>>
08/08/20162:56PMDJNAllergan Revenue Increases, Though Loss Widens--Update
By Jonathan D. Rockoff and Austen Hufford Allergan PLC's chief executive said the company "doesn't need" to make a big acquisition, as the drugmaker reported strong sales of many products but a doubling of its quarterly loss, due to the impact of discontinued operations. The Wall Street Journal reported... More...>>
08/08/201611:59AMDJNMARKET SNAPSHOT: Stocks Retreat From Records As Health-care Stocks Slump
By Ellie Ismailidou and Barbara Kollmeyer, MarketWatch Mattress Firm bounces higher on deal news; oil gains boost energy shares U.S. stocks were trading moderately lower Monday as Wall Street caught its breath after Friday's record-setting rally fueled by jobs data that helped revive investors' confidence in... More...>>
08/08/201610:20AMDJNMARKET SNAPSHOT: Stocks Fight To Maintain Record-setting Pace After Jobs-fueled Advance
By Ellie Ismailidou and Barbara Kollmeyer, MarketWatch Mattress Firm bounces higher on deal news The S&P 500 struggled to maintain flight on Monday, after briefly touching an all-time intraday record in early trade, following jobs data on Friday that helped revive investors' confidence in the U.S. economy. A sharp... More...>>
08/08/20166:45AMBWREPEAT/FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head & Neck Squamous Cell ...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with... More...>>
08/05/20167:30PMBWFDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head & Neck Squamous Cell Carcino...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with... More...>>
08/05/201612:58PMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--4th Update
By Peter Loftus, Jonathan D. Rockoff and Anne Steele In a surprise finding that raises questions about the potential for a new class of cancer drugs that harness the body's immune system, Bristol-Myers Squibb Co. said its drug Opdivo wasn't significantly better than chemotherapy in a study of patients with newly... More...>>
08/05/201610:36AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--3rd Update
By Anne Steele Bristol-Myers Squibb Co. said a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 17% to $62.21 in early trading, erasing roughly $22 billion of the company's market value and... More...>>
08/05/201610:15AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--2nd Update
By Anne Steele Bristol-Myers Squibb Co. said a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 16% to $63.07 in early trading. Meanwhile, shares of Merck & Co. rose 5.6% as the result suggests... More...>>
08/05/20169:39AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study--Update
By Anne Steele Bristol-Myers Squibb Co. said a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 19% to $61 in premarket trading. Meanwhile, shares of Merck & Co. rose 11% as the results suggest... More...>>
08/05/20169:20AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study
Bristol-Myers Squibb Co. said results for a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 17% to $62.60 in premarket trading. Meanwhile, shares of Merck & Co. rose 10% as the results suggest... More...>>
08/05/20169:12AMDJNBristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer Study
By Anne Steele Bristol-Myers Squibb Co. said results for a trial investigating its blockbuster cancer drug Opdivo as a therapy for advanced non-small cell lung cancer failed to meet its primary endpoint. Shares in the company dropped 17% to $62.60 in premarket trading. Meanwhile, shares of Merck & Co. rose 10% as the... More...>>
08/05/20168:00AMBWMerck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic I...
Marketing Authorization Application to the European Medicines Agency Currently Under Review Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293, an investigational follow-on... More...>>
08/04/201611:21AMDJNMARKET SNAPSHOT: U.S. Stocks Choppy After Bank Of England Stimulus, Mixed Data
By Ellie Ismailidou and Barbara Kollmeyer, MarketWatch U.S. jobless claims rise, factory orders tumble U.S. stocks dipped in and out of negative territory Thursday, struggling to hold on to early gains sparked by a decision by the Bank of England to cut its key interest rate for the first time in seven years and to expand... More...>>
08/03/20163:03AMDJNIn Quest to Grow, Rivals Woo Biogen -- WSJ
By Dana Mattioli, Jonathan D. Rockoff and Dana Cimilluca Biotechnology giant Biogen Inc. has drawn takeover interest from drug companies including Merck & Co. and Allergan PLC, raising the possibility of another huge deal in the health-care industry. Merck and Allergan have each sounded out Biogen on the possibility... More...>>
08/02/20167:59PMDJNBiogen Draws Takeover Interest from Rival Drugmakers--2nd Update
By Dana Mattioli, Jonathan D. Rockoff and Dana Cimilluca Biotechnology giant Biogen Inc. has drawn takeover interest from drug companies including Merck & Co. and Allergan PLC, raising the possibility of another huge deal in the health-care industry. Merck and Allergan have each sounded out Biogen on the possibility... More...>>
08/02/20165:00PMBWMerck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cance...
Approval Based on Trial Results Demonstrating Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20160830 13:10:43